CytoDyn Inc. CYDY Archives

ThursdayJan 10, 2019 9:16 am

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Appoints New Member to Board of Directors

Biotechnology company CytoDyn (OTCQB: CYDY) this morning announced the appointment of David F. Welch, Ph.D., Founder, Chief Innovation Officer and Director of Infinera Corporation, to the CytoDyn Board of Directors. Dr. Welch has a notable background including strategic planning expertise and broad capital markets experience. As an investor in the company, he appreciates the potential of CYDY’s leronlimab in targeting multiple disease processes. “We are pleased to add Dr. Welch to our Board of Directors. He is a pioneer in the field of optical devices and optical transport with a strong scientific background,” CytoDyn president and CEO Dr. Nader Pourhassan…

TuesdayJan 08, 2019 9:29 am

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) to Present at Biotech Showcase Conference

Biotechnology company CytoDyn (OTCQB: CYDY) this morning announced that it will be presenting at the Biotech Showcase at the Hilton San Francisco Union Square in San Francisco, California on January 9, 2019 at 10:30 AM PT. An update on the company’s clinical development programs and objectives for leronlimab (PRO 140) will be co-presented by president and CEO Nader Pourhassan, Ph.D. and chief medical officer and vice chairman Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P. The presentation will provide insights regarding the company’s plans for 2019, including details on its first BLA submission of PRO 140 anticipated to occur during…

MondayJan 07, 2019 9:57 am

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Names Richard G. Pestell, M.D., Ph.D. as Board Vice Chairman, Expanding Leadership Role in Advancement of Company Initiatives

Biotechnology company CytoDyn (OTCQB: CYDY) today announced the election of its Chief Medical Officer and Director Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P. to the additional position of vice chairman of the board of directors. In this added role Pestell, an internationally renowned clinician and cancer researcher and defining force in CCR5 antagonist research, will advance and accelerate CYDY’s initiatives in seeking non-dilutive licensing opportunities in cancer and immunology. “We are honored to have Dr. Pestell serve as our Vice Chairman,” CytoDyn President and Chief Executive Officer Nader Pourhassan stated in the news release. “He is a world renowned…

FridayJan 04, 2019 12:13 pm

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Foresees Market Availability of PRO 140 by 2020

Biotechnology company CytoDyn (OTCQB: CYDY) anticipates that it will attain final FDA approval for its HIV treatment, PRO 140, by the fourth quarter of 2019. The company expects market availability will follow by 2020. An article further discussing the company reads, “Leronlimab (PRO 140) is part of a new class of HIV drugs that protects healthy cells from infection by the virus. It’s a humanized IgG4 monoclonal antibody that binds to CCR5, a cellular co-receptor with multiple roles including implications for HIV infection, tumor metastasis and immune signaling. Less frequent dosing, minimal side effects and hardly any toxicity are among…

WednesdayDec 26, 2018 10:29 am

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Appoints Chief Technology Officer Nitya G. Ray, Ph.D.

Biotechnology company CytoDyn (OTCQB: CYDY) today announced that it has named Nitya G. Ray, Ph.D. to serve as its new chief technology officer – head of process sciences, manufacturing & supply chain. Dr. Ray, from November 2015 to June 2017, served as CytoDyn’s senior vice president of manufacturing. Most recently, he served Actinium Pharmaceuticals, Inc. as its executive vice-president, head of product development, manufacturing and supply chain. Prior to joining CytoDyn in 2015, Dr. Ray was senior vice president at Progenics Pharmaceuticals, Inc. and, during his 14-year tenure there, was responsible for manufacturing, process and analytical sciences, and quality control.…

WednesdayDec 12, 2018 10:19 am

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Appoints Dr. Scott Kelly as Chairman of the Board

Biotechnology company CytoDyn (OTCQB: CYDY) today announced that its board of directors has appointed Scott A. Kelly, M.D., FAAPMR as its chairman. Dr. Kelly has served on CytoDyn’s board since April 2017, and he succeeds Anthony D. Caracciolo, who will continue to serve as a company director. “We are delighted to have Scott serve as our chairman of the board and look forward to supporting him in his new role,” CytoDyn President, CEO and Director of Nader Pourhassan stated in the news release. “Scott has been instrumental in our strategy to aggressively develop leronlimab (“PRO 140”) in certain immunology and…

TuesdayDec 11, 2018 12:21 pm

CytoDyn, Inc. (CYDY) Expects FDA Approval for PRO 140 in HIV by Q4 2019, $500M Revenue Forecast for 2020

PRO 140 has FDA fast track designation that allows accelerated approval The drug protects healthy cells from HIV infection by binding to CCR5 cellular co-receptor Market for PRO 140 as a single agent therapy projected at about $4 billion annually CYDY recently initiated its first cancer trial in triple negative breast cancer, targeting an unmet medical need CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV), expects to gain final FDA approval for its HIV treatment, PRO 140, by the fourth…

ThursdayDec 06, 2018 9:53 am

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) to Host Conference Call, Provide Business Update on December 12, 2018

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced that President and CEO Nader Pourhassan, Ph.D., and Chief Medical Officer Richard Pestell, M.D., Ph.D., F.A.C.P., M.B.A., will host an investment community conference call on Wednesday, December 12, at 4:00 p.m. ET. To access the call, interested parties should dial 877-407-2986 (U.S. and Canada) or 201-378-4916 (international). A live audio webcast of the call may also be accessed via CytoDyn’s corporate website at www.CytoDyn.com under the Investors section, and it will be archived for 60 days following the conclusion of the call. Web participants are encouraged to visit the website 15…

ThursdayNov 29, 2018 10:40 am

QualityStocksNewsBreaks – CytoDyn Inc.’s (CYDY) PCaTest Clinical Study Results Demonstrate Added Value to Gleason Score, Further Support FDA filing

Biotechnology company CytoDyn (OTCQB: CYDY) today announced recent clinical study results showing that its PCaTest provides substantial additive value for predicting outcomes for prostate cancer patients compared to the Gleason score, the current standard for prostate cancer diagnosis. The new findings support CYDY’s strategy for seeking FDA approval for the PCaTest. “Unfortunately, current tests not able to precisely determine whether an individual’s cancer will result in death if not treated aggressively,” CytoDyn Chief Medical Officer and developer of the PCaTest Richard Pestell , M.D., Ph.D., F.A.C.P., M.B.A., stated in the news release. “On the other hand, aggressive treatment for prostate…

TuesdayNov 27, 2018 10:07 am

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Scheduled to Present at Two Conferences in December

CytoDyn (OTCQB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, this morning announced that Nader Pourhassan, Ph.D., president and CEO and Richard Pestell, M.D., Ph.D., F.A.C.P., M.B.A., Chief Medical Officer, will present at two investment conferences during the month of December. First, taking place on Tuesday, December 4, 2018 at 1:30 p.m. ET, the company will present at the 11th Annual LD Micro Main Event at the Luxe Sunset Boulevard Hotel in Los Angeles. On Thursday, December 13, 2018, the company will present at the Singular Research “Best of the Uncovered” – Small…

Site Search

Company Search

Tag: CytoDyn Inc. CYDY